Obesity and Diabetes
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Published in Medical Verdicts and Law Weekly, July 23rd, 2009
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients. This Phase 2 study successfully characterized patients who responded best to treatment and also provided important information to inform dose selection.
At 28 weeks, evaluable patients with a starting body mass index (BMI) less than 35 kg/m2 (n=3D149), and treated with the highest pramlintide/metreleptin doses, experienced significantly more weight loss on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- American Civil Liberties Union
ACLU Seeks End To Censorship of Religious Material By Virginia Jail - American Federation of Government Employees
TSA Union Thanks Lawmakers for Supporting H.R. 1881 - American Hospital Association
Economy Forces Most Wired Hospitals to Look Closely at IT Spending - Americans United for Life
AUL President to Senate Judiciary Committee: Ask Top 10 Questions to Judge Sotomayor - AMN Healthcare
Leading Nursing Web site, NurseZone.com Wins Award for Journalism Excellence - AmWINS Group Benefits
Six Ways to Fix the American Healthcare System - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
